#303: The AI Stocks No One is Talking About: Biotech Boom

This week, Emmet and Mike are digging into one of the hottest trends of our futuristic world: human longevity. We’ve all seen Bryan Johnson on our social feeds, but the business of living longer is more than just a meme. Today, new-age pharmaceutical companies are leveraging AI to reinvent the drug development process—making it faster, cheaper, and more customizable. If they’re successful, it could become one of the most important scientific innovations of all time. This raises the question: how do you invest in it? Emmet sees four categories: Metabolic longevity — Eli Lilly, Novo Nordisk Early disease detection — Guardant Health, Exact Sciences Longevity infrastructure — Thermo Fisher, Danaher Corp Moonshots — Recursion Pharmaceuticals Inc But which stocks are the lads’ favorites? Mike favors Tempus AI (TEM) for its two-pronged business model, composed of diagnostics and data. The diagnostics side is similar to Guardant Health, focusing on hereditary and sequencing tests. The data side consists of vast libraries of medical data that are licensed to other pharma and biotech companies, enabling things like trial design, pre-validation, and patient enrollment. They also have some impressive stats: net revenue retention sits at 126%, and they have over a billion dollars in backlog. Emmet goes with a stock he previously added to his watchlist, but later removed due to its complexity: Recursion Pharmaceuticals. It has a validated, full-stack platform for AI-driven drug discovery, but currently licenses data from Tempus AI. It recently achieved its first patented result from its AI system, which is considered a major breakthrough. They wrap up by sharing which stock they would invest in today. In celebration of St. Patrick’s Day, all of our services are on sale. From Horizon to Prophet, it’s a great time to find your next life-changing investment (at a discount). Importantly, our Insider Bot lives inside Horizon so if you want to invest like a CEO or CFO now is the time. To lock in your special rate, email frank@mywallst.com Psssst…. We don’t think you’ll want to miss this year’s Investicon. Grab your early bird tickets now: Become a successful investor by checking out all the content MyWallSt has to offer: 📩 Email us: pod@mywallst.com 📚 Learn the fundamentals of investing by downloading our free Learn app: 💻 Keep updated on stock market news by visiting our blog: 🎧 Tune in to our podcast Stock Club to stay updated on weekly news: 🎉 Follow MyWallSt on social: ❌ X: @MyWallStHQ 💃 TikTok: @MyWallSt 📸 Instagram: @MyWallSt 🖥️ Facebook: @MyWallSt 👔 LinkedIn: MyWallSt 00:00 Intro01:31 Why Longevity Matters07:31 Demis Hassabis on the Future of AI15:08 Longevity Investing Archetypes24:16 Tempus AI Overview31:39 Recursion Pharma Pitch45:07 10K Portfolio Split

You can listen to #303: The AI Stocks No One is Talking About: Biotech Boom online on Radio and Podcast. Open the player on this page to stream the available audio.

#303: The AI Stocks No One is Talking About: Biotech Boom is an episode from Stock Club by MyWallSt.

This episode is 00:47:38 long.

This episode was published on Mar 19, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Stock Club when more episodes are available from the podcast feed.